AMIT CHAUDHARY

Dr. AMIT CHAUDHARY


Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
PDF file
ZTZhewei Tang
Zhewei Tang
MFMingqian Feng
Mingqian Feng
WGWei Gao
Wei Gao
YPYen Phung
Yen Phung
WCWeizao Chen
Weizao Chen
MHMitchell Ho
Mitchell Ho
Monoclonal antibodies against mesothelin are being evaluated for the treatment of mesothelioma and multiple forms of cancers, and show great promise for clinical development for solid cancers. Antibodies against mesothelin have been shown to act via immunotoxin-based inhibition of tumor growth and induction of antibody-dependent cell-mediated cytotoxicity (ADCC). However, complement-dependent cytotoxicity (CDC), considered an important additional mechanism of therapeutic antibodies against tumors, is inactive for such antibodies. Here, we used phage display antibody engineering technology and synthetic peptide screening to identify SD1, a human single-domain antibody to mesothelin. SD1 recognizes a conformational epitope at the C-terminal end (residues 539–588) of mesothelin close to the cell surface. To investigate SD1 as a potential therapeutic agent, we generated a recombinant human Fc (SD1-hFc) fusion protein. Interestingly, the SD1-hFc protein exhibits strong CDC activity, in addition to ADCC, against mesothelin-expressing tumor cells. Furthermore, it causes growth inhibition of human tumor xenografts in nude mice as a single agent. SD1 is the first human single-domain antibody targeting mesothelin-expressing tumors, shows potential as a cancer therapeutic candidate, and may improve current antibody therapy targeting mesothelin-expressing tumors. Mol Cancer Ther; 12(4); 416–26. ©2013 AACR.

1 January 2006 in Journal of Carcinogenesis
Verified
Journal Article
Open access
ACAMIT CHAUDHARY
AMIT CHAUDHARY
VJVinod Jain
Vinod Jain
RDRama S Dwivedi
Rama S Dwivedi
SMSamir Misra
Samir Misra
To report a 45 year old lady presenting with proximal jejunal gangrene due to invasive Aspergillosis. The patient was undergoing adjuvant chemotherapy for advance carcinoma of breast (Stage IV). The patient was referred to our surgical emergency for acute abdominal symptoms for 6 hours. Histopathology revealed bowel wall necrosis and vascular invasion by Aspergillus Fumigatus. Postoperative recovery was uneventful and the patient received Amphotericin-B (1 mg/kg/day) for invasive aspergillosis. Invasive pulmonary aspergillosis was confirmed by isolating Aspergillus Fumigatus from bronchoalveolar lavage and by a positive circulating galactomannan test (ELISA Assay). Detailed history revealed dry cough and two episodes of haemoptesis for 2 weeks. Haemogram and counts revealed anemia and neutropenia. Plain X-ray of the abdomen showed multiple air fluid levels and ultrasound of the abdomen revealed distended bowel loops. On exploration small bowel was found to be gangrenous. The patient was successfully managed by supportive treatment and conventional intravenous Amphotericin-B for 2 weeks. The lady was discharged one week after completion of antifungal therapy and one month later she underwent toilet mastectomy. The lady came to follow up for 1 year and she is currently under hormone therapy. With the emergence of new and powerful immunosuppressive, anticancer drugs and potent antibiotics the survival of transplant and critically ill patients has remarkably increased but it has shown a significant rise in the incidence of invasive opportunistic fungal infections. We conclude hat the diagnosis of invasive gastrointestinal aspergillosis may be considered in a neutropenic patient with acute abdominal symptoms.

7 October 2025 in Langmuir
Verified
Journal Article
Closed access
ACAMIT CHAUDHARY
AMIT CHAUDHARY
APAnup K. Prasad
Anup K. Prasad
LMLisa Martin
Lisa Martin
APAjay Singh Panwar
Ajay Singh Panwar

1 October 2022 in Letters in Drug Design & Discovery
Verified
Journal Article
Closed access
PDF file
SPSonu Pahal
Sonu Pahal
ACAMIT CHAUDHARY
AMIT CHAUDHARY
SSSangeeta Singh
Sangeeta Singh
Background: Amyotrophic lateral sclerosis (ALS) is an uncommon and progressive neurological illness that predominantly includes the neurons liable for voluntary muscular activities. Starting from weakness or stiffness in muscles, this gradually exploits the strength and ability to speak, eat, move, and even breathe. Its exact mechanism is still not clear, but mutations in the SOD1 gene have been reported to cause ALS, and some studies also found involvement of SOD1 overexpression in the pathogenesis of ALS. As of now, there is no remedy available for its cure. Objective: The objective of this study is to identify the potential inhibitors for wild type 1HL5, l113T mutant, and A4V mutant of SOD1 (Superoxide Dismutase 1) protein. Methods: In this study, in silico approaches like virtual screening, molecular docking, pharmacokinetic parameters study, and molecular dynamics simulation were used to identify the best potential inhibitors against wild type and mutant SOD1 protein. Results: On the basis of binding affinity and binding energy, the top three compounds ZINC000095486263, ZINC000095485989, and ZINC000028462577 were observed as the best compounds. In the case of 1HL5, ZINC000095486263 had the highest binding affinity with docking score - 10.62 Kcal/mol, 1UXM with ZINC000095485989 had the highest docking score -12.03 Kcal/mol, and 4A7V with ZINC000028462577 was found -11.72 Kcal/mol. Further, Molecular Dynamic Simulations (MDS) results showed that the ZINC000095486263, ZINC000095485989, and ZINC000095485956 compounds were formed a stable complex with 1HL5, 1UXM, and 4A7V respectively. Conclusions: After analyzing the results, we hereby conclude that natural compounds such as ZINC000095486263, ZINC000095485989, and ZINC000095485956 could be used as a potential inhibitor of 1HL5, 1UXM, and 4A7V respectively for ALS treatment and could be used as a drug. Further, In vivo/vitro study of these compounds could be a future direction in the field of drug discovery.

30 August 2025 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
AGArushi Gupta
Arushi Gupta
SPSonu Pahal
Sonu Pahal
VKVivek Kumar
Vivek Kumar
ACAMIT CHAUDHARY
AMIT CHAUDHARY

10 June 2018 in International Journal of Current Microbiology and Applied Sciences
Verified
Journal Article
Open access
KLKanhaiya Lal
Kanhaiya Lal
RKRajesh Kumar
Rajesh Kumar
VSVishal Singh
Vishal Singh
ACAMIT CHAUDHARY
AMIT CHAUDHARY
HYHarikant Yadav
Harikant Yadav
AKAshvani Kumar
Ashvani Kumar
International Journal of Current Microbiology and Applied Sciences ISSN:2319-7692(Print), ISSN:2319-7706(Online) is a multidisciplinary peer-reviewed journal with reputable academics and experts as members of its Editorial Board. The Current Microbiology aims to publish all the latest and outstanding research articles. Review and letters in all areas of major importance to techniques of microbiology and applied research with publishes high quality of review and research articles on novel aspects of Microbiology including Environmental, Food, Agricultural, Medical, Pharmaceutical, Veterinary, Soil, Water and Biodeterioration.